Literature DB >> 6255035

Infection with herpes simplex virus and cell-mediated immunity after marrow transplant.

J D Meyers, N Flournoy, E D Thomas.   

Abstract

The relationship between herpes simplex virus (HSV) infection and specific cell-mediated immunity was investigated in 141 patients before and for the first four months after marrow transplant. Sixty-two (82%) of 76 seropositive patients but only one of 65 seronegative patients developed HSV infection. Lymphocyte responses to HSV antigen were suppressed immediately after transplant and subsequently became reactive in those patients with HSV infection. The presence or absence of antibody to HSV in the donor before transplant did not influence the response. Seventy long-term survivors of marrow transplant were also studied. Among 60 patients who had pretransplant serum available for study, 26 (68%) of 38 who had been seropositive before transplant had positive responses compared with none of 22 who had been seronegative. Recovery of responsiveness to HSV antigen after marrow transplant is primarily related to recurrent virus infection and not to the pretransplant immune status of the donor.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6255035     DOI: 10.1093/infdis/142.3.338

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  26 in total

1.  Intravenous penciclovir for treatment of herpes simplex infections in immunocompromised patients: results of a multicenter, acyclovir-controlled trial. The Penciclovir Immunocompromised Study Group.

Authors:  H M Lazarus; R Belanger; A Candoni; M Aoun; R Jurewicz; L Marks
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

Review 2.  Herpesvirus infections in organ transplant recipients.

Authors:  Frank J Jenkins; David T Rowe; Charles R Rinaldo
Journal:  Clin Diagn Lab Immunol       Date:  2003-01

Review 3.  Prevention of viral infections after bone marrow transplantation.

Authors:  U Schuler; G Ehninger
Journal:  Ann Hematol       Date:  1992-06       Impact factor: 3.673

4.  Complex management of resistant oral herpes simplex virus infection following hematopoietic stem cell transplantation: potential role of topical cidofovir.

Authors:  Joel B Epstein; Sara Gharapetian; Ali R Rejali; Rachel Zabner; Michael Lill; Dimitrios Tzachanis
Journal:  Support Care Cancer       Date:  2016-05-10       Impact factor: 3.603

5.  Management of infection in the neutropenic patient.

Authors:  R E Marcus; J M Goldman
Journal:  Br Med J (Clin Res Ed)       Date:  1986-08-16

Review 6.  The Type I Interferon Response and Age-Dependent Susceptibility to Herpes Simplex Virus Infection.

Authors:  Daniel Giraldo; Douglas R Wilcox; Richard Longnecker
Journal:  DNA Cell Biol       Date:  2017-03-09       Impact factor: 3.311

7.  [Oral prophylaxis of herpes infections using acyclovir following bone marrow transplantation: a clinical and clinico-pharmacological study].

Authors:  G Ehninger; A Vallbracht; K Schüch; I Kumbier; R Dopfer; H Schmidt; P Ostendorf
Journal:  Klin Wochenschr       Date:  1986-06-16

8.  Enumeration of viral antigen-reactive helper T lymphocytes in human peripheral blood by limiting dilution for analysis of viral antigen-reactive T-cell pools in virus-seropositive and virus-seronegative individuals.

Authors:  K A Clouse; P W Adams; C G Orosz
Journal:  J Clin Microbiol       Date:  1989-10       Impact factor: 5.948

9.  2-[4,5-Difluoro-2-(2-fluorobenzoylamino)-benzoylamino]benzoic acid, an antiviral compound with activity against acyclovir-resistant isolates of herpes simplex virus types 1 and 2.

Authors:  Mårten Strand; Koushikul Islam; Karin Edlund; Christopher T Oberg; Annika Allard; Tomas Bergström; Ya-Fang Mei; Mikael Elofsson; Göran Wadell
Journal:  Antimicrob Agents Chemother       Date:  2012-08-20       Impact factor: 5.191

10.  Herpes simplex virus and oral mucositis in children with cancer.

Authors:  G Carrega; E Castagnola; A Canessa; P Argenta; R Haupt; G Dini; A Garaventa
Journal:  Support Care Cancer       Date:  1994-07       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.